National Pharmaceutical Pricing Authority

Drugs used to treat diseases that are a public health problem in India, are comparatively cost effective and aligned with the current treatment guidelines are included in the National List of Essential Medicines

Pharma pricing regulator fixes cost of 84 formulations; medicines for Type-2 diabetes, blood pressure

The drug formulations whose prices have been fixed include those used in the treatment of type 2 diabetes, high blood pressure, and gastrointestinal disorders.

NPPA asks drug firms to cut prices in wake of GST rate reduction

The NPPA is mandated to fix and revise the prices of controlled bulk drugs and formulations, and to enforce prices and availability of the medicines in the country.

Coronavirus pandemic | Centre may launch campaign to curb hoarding of face masks, hand sanitizers

The Centre is looking at launching an awareness campaign so that people stop hoarding these products in large numbers

No shortage of APIs and formulations in the country: Govt

NPPA has also informed that it has not received any reference from pharma associations regarding steep increase in price of medicines due to outbreak of COVID-19 (coronavirus) in China, he added.

Reporter's Take | Government scrambles to address shortage of rabies vaccine

The National Pharmaceutical Pricing Authority has asked manufacturers and distributors to immediately supply stocks in areas where a shortage has been reported.

Prices of 390 non-scheduled cancer medicines slashed by up to 87%: Govt

The National Pharmaceutical Pricing Authority (NPPA) on February 27 had brought 42 non-scheduled anti-cancer drugs under price control, capping trade margin at 30 percent.

Govt caps trade margins of 42 cancer drugs

Currently, 57 anti-cancer drugs are under price control as scheduled formulations.

Govt increases stent prices by around 2%

Drug price regulator NPPA has increased price of stents by around 2 percent effective tomorrow after taking into account wholesale price index.

NPPA identifies 634 suspected cases of overcharging

National Pharmaceutical Pricing Authority (NPPA), after analysis of market data and associated reports of December 2016 submitted by AIOCD-AWACS, has identified 634 cases where non-compliance of notified ceiling price is suspected, Minister of State for Chemicals and Fertilisers, Mansukh L Mandaviya, said in a written reply to the Lok Sabha.

Few more drugs to come under price control: NPPA

The regulator has been fixing and revising the prices of drugs, and by January this year, when it had slashed the prices of 33 drugs, over 620 drugs had been placed under the price control sine April 2016.

Getting complaints on excessive pricing of drugs: NPPA

"Our priority is to fix the prices of drugs as soon as possible. We do get complaints and representations on the excessively high prices of other drugs", Bhupendra Singh, Chairman of NPPA told CNBC-TV18.

NPPA asks hospitals to display revised price list of stents

Regulator NPPA today asked hospitals to prominently display revised price list of stents while ordering manufacturers and importers to report to it in case of withdrawal or non-availability of products.

Govt to act against cos creating artificial shortage of stents

Government today said it is keeping a close watch on some companies trying to create an artificial shortage of life-saving coronary stents and stringent action will taken against those engaging in unethical practices.

After pricing cap, NPPA warns of 'artificial' shortage of stents

NPPA said the government can direct any manufacturer to maintain, import or increase supplies of cardiac stents in public interest, and a designated officer of government of both State and Central can enter, search and seize stocks of stents anywhere in the trade channel – if they found to be hoarding them.

NPPA's price caps on stents may hurt manufacturers: Medanta

The National Pharmaceutical Pricing Authority‘s new policy on stent is welcome as it improves access and brings in transparency, but capping coronary stent prices may hurt manufacturers, according to Medanta Chairman Naresh Trehan.

Stents to get cheaper by as much as 85% as drug body caps price

NPPA capped the prices of bare metal stent at Rs.7260 and drug eluting stent (DES) and biodegradable stents at Rs.29,600. Both the prices were exclusive of value added tax. DES constitutes 95 percent of the market.

ADEH asks Govt to review pricing of coronary stents

Expressing serious concern over affordability in health care, a network of doctors today asked the Centre to review pricing of coronary stents to stop the device industry from making "huge" profits.

79 demand notices issued to drug cos for overcharging: Govt

National drug price regulator NPPA has issued 79 demand notices to pharmaceutical companies for overcharging for non-scheduled medicines, Parliament was informed today.

Govt may delink price control from essential drugs, revamp NPPA

The National Pharmaceutical Pricing Authority in its present form could be disbanded, reports The Economic Times. The government will likely assume power to set prices of essential medicines.

In blow to pharmas, SC dismisses plea against 2014 notification

The Supreme Court has dismissed the plea against the 2014 notification seeking to regulate prices of 108 diabetic and cardiac drugs. A whole list of listed companies could get affected by order.

NPPA cuts prices of cancer, HIV, cardiac drugs by around 25%

"National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices of 24 scheduled formulations of schedule-I under Drugs (Price Control) Amendment Order, 2016," the drug pricing regulator said in a order on its website.

NPPA reduces prices of 42 drugs by upto 15%

Prices of 42 essential medicines used in treatment of various ailments including tuberculosis, cancer, cardiac diseases, tuberculosis, asthma, epilepsy, rheumatoid arthritis and depression have been capped by the government, reducing their cost by up to 15 percent

NPPA fixes ceiling price of 54 drug formulations

"National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices of 54 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016 and retail price of two formulations under DPCO, 2013," the regulator said in a statement.